drugset / Trial / NCT06434350

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

NCT06434350

Phase 1/2 Recruiting 41 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.

Timeline

Start
2024-10-10
Primary completion
2027-09-24
Completion
2027-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Enfortumab Vedotin Other / unclassified Intravenous